Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder

Changsu Han; Moon Soo Lee; Chi Un Pae; Young Hoon Ko; Ashwin A. Patkar; In Kwa Jung

doi:10.1016/j.pnpbp.2007.04.017

Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder

Changsu Han, Moon Soo Lee, Chi Un Pae, Young Hoon Ko, Ashwin A. Patkar, In Kwa Jung

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n = 11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients.

Original language	English
Pages (from-to)	1219-1223
Number of pages	5
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	31
Issue number	6
DOIs	https://doi.org/10.1016/j.pnpbp.2007.04.017
Publication status	Published - 2007 Aug 15
Externally published	Yes

Bibliographical note

Funding Information:
Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033); was on the speakers' bureau of Janssen, Otsuka, and MSD. Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Janssen supplied the study medication.

Keywords

Bipolar disorder
Long-acting injections
Maintenance
Risperidone

ASJC Scopus subject areas

Pharmacology
Biological Psychiatry

Access to Document

10.1016/j.pnpbp.2007.04.017

Cite this

@article{d89456f3b332408f949c29deb0f91f51,

title = "Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder",

abstract = "This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n = 11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients.",

keywords = "Bipolar disorder, Long-acting injections, Maintenance, Risperidone",

author = "Changsu Han and Lee, {Moon Soo} and Pae, {Chi Un} and Ko, {Young Hoon} and Patkar, {Ashwin A.} and Jung, {In Kwa}",

note = "Funding Information: Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033); was on the speakers' bureau of Janssen, Otsuka, and MSD. Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Janssen supplied the study medication.",

year = "2007",

month = aug,

day = "15",

doi = "10.1016/j.pnpbp.2007.04.017",

language = "English",

volume = "31",

pages = "1219--1223",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder

AU - Han, Changsu

AU - Lee, Moon Soo

AU - Pae, Chi Un

AU - Ko, Young Hoon

AU - Patkar, Ashwin A.

AU - Jung, In Kwa

N1 - Funding Information: Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033); was on the speakers' bureau of Janssen, Otsuka, and MSD. Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Janssen supplied the study medication.

PY - 2007/8/15

Y1 - 2007/8/15

N2 - This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n = 11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients.

AB - This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n = 11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients.

KW - Bipolar disorder

KW - Long-acting injections

KW - Maintenance

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=34447563990&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.04.017

DO - 10.1016/j.pnpbp.2007.04.017

M3 - Article

C2 - 17532106

AN - SCOPUS:34447563990

SN - 0278-5846

VL - 31

SP - 1219

EP - 1223

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

IS - 6

ER -

Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this